<DOC>
	<DOCNO>NCT02503644</DOCNO>
	<brief_summary>Systemic sclerosis ( SSc ) , scleroderma connective tissue disease autoimmune origin . It life-threatening orphan disease severe physical psychosocial consequence . IVA337 novel mechanism action study design compare IVA337 two dose level placebo control treatment . Patients unaware treatment receive randomize one three treatment arm , either IVA337 400mg bid , IVA337 600mg bid placebo bid . They receive drug 48 week time assessment make monitor efficacy safety treatment .</brief_summary>
	<brief_title>Proof-of-concept Trial IVA337 Diffuse Cutaneous Systemic Sclerosis</brief_title>
	<detailed_description>Study design : randomize , double-blind , placebo-controlled , multicentre phase 2 proof-of-concept trial IVA337 treatment DcSSc . The treatment randomly assign . The randomisation stratify background therapy ensure even distribution background therapy among treatment group . There 3 parallel treatment group : placebo , IVA337 400mg bid IVA337 600mg bid ( identical capsule 200mg IVA337 placebo ) . Both , patient investigator blind . The treatment last 48 week . A follow-up assessment take place 12 week last dose .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<criteria>Informed Consent document signature Systemic sclerosis accord ACR/EULAR 2103 criterion ( van de Hoogen 2013 ) Diffuse cutaneous SSc subset accord LeRoy 's criterion Diagnosis within past 3 year define first nonRaynaud 's symptom MRSS 10 25 Age 18 75 , male female Patients stable treatment ( &gt; 3 month ) prednisone ≤ 10 mg , methotrexate≤ 20 mg/w , azathioprine ≤ 150 mg/d , mycophenolate mofetil ≤ 2g/d , leflunomide ≤ 20 mg/d may include study ; therapy must maintain background therapy . Cyclophosphamide past 3 month Requirement IV prostanoids pulmonary hypertension last 3 month Renal insufficiency define creatinine clearance le 30 ml/min ( CKDEPI MDRD formula ) and/or past/current renal crisis Hepatic impairment i.e . primary biliary cirrhosis unexplained persistent liver function abnormality , Gallbladder disease ( Cholelithiasis exclusion criterion ) Diabetic ketoacidosis Severe cardiac ( LVEF &lt; 45 % ) and/or pulmonary disease ( FVC &lt; 50 % pulmonary hypertension proven right heart catheterisation ) History heart failure , symptomatic coronary artery disease , significant ventricular tachyarrhythmia , stent placement , coronary artery bypass surgery , and/or myocardial infarction . Recipient solid organ transplant Gastrointestinal involvement prevent oral administration study drug Chronic infection , positive serology infection hepatitis B C. Pregnancy , Lactation . Woman childbearing potential unwilling use medically acceptable form birth control History malignancy within last 5 year , except resect basal squamous cell carcinoma , treat cervical dysplasia , treat situ cervical cancer A recent history alcohol drug abuse , noncompliance medical therapy Participation clinical study involve another investigational drug device within 4 week Pretreatment Visit Laboratory parameter pretreatment visit show follow abnormal result : transaminase &gt; 2x upper limit normal ( ULN ) and/or bilirubin &gt; 2x ULN ; neutrophil count &lt; 1,500/mm3 ; platelet count &lt; 100,000/mm3 ; haemoglobin &lt; 9 g/dL Contraindications class drug study ( PPAR agonist ) , e.g . know hypersensitivity allergy class drug investigational product Any condition treatment , opinion investigator , place subject unacceptable risk patient trial Cotherapy biologics : Washout period : Any antiTNF agent last 3months : adalimumab , certolizumab , etanercept , golimumab , infliximab ; abatacept last 3 month ; rituximab last 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>diffuse cutaneous systemic sclerosis</keyword>
	<keyword>scleroderma</keyword>
	<keyword>IVA337</keyword>
	<keyword>dcSSc</keyword>
</DOC>